Hyloris Lines Up Hectic Year Of Clinical Trials And Major US Launch
Value-Added Medicines Developer Quietly Reframes 30-Asset Goal
Hyloris has an eventful year ahead as it plans to conduct numerous trials for products in its ever-expanding pipeline and launch Maxigesic IV in the US.
